Nanologica delivers NLAB SIV™ to a customer in Asia to a value of over MSEK 4

Stockholm, Sweden

Nanologica has made the first delivery of the company’s non-silica-based purification media NLAB Siv™ to a customer in Asia against an order received in November. The value amounts to over MSEK 4.

NLAB Siv™ is a non-silica-based purification media that has been developed together with a customer who sells a number of pharmaceutical products. NLAB Siv™ is used for purification through preparative chromatography and the customer has expressed a desire to replace the purification media they currently use in the production of one of their drugs. Manufacturing of NLAB Siv™ takes place at a manufacturing partner in Europe. Development has been carried out with the customer for several years and evaluation of smaller quantities has been made during this period.

” The customer will now evaluate NLAB Siv™ in full production. It is not unlikely that further product development may be needed, but if the evaluation is successful we expect that our product will gradually replace the product they use today, which they are keen to replace”, Nanologica’s CEO Andreas Bhagwani comments.

Nanologica’s main focus will continue to be silica-based products for preparative chromatography, but the company will continuously evaluate additional potential products in chromatography in order to expand the offering to customers and increase the company’s addressable market.

For further information, please contact
Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

Links